Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$247.00 USD
+1.83 (0.75%)
Updated Jun 27, 2024 04:00 PM ET
After-Market: $247.18 +0.18 (0.07%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Brokerage Reports
Alnylam Pharmaceuticals, Inc. [ALNY]
Reports for Purchase
Showing records 401 - 414 ( 414 total )
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Another day, another brick on Alnylam''s IP wall; early, broad, fundamental RNAi patent allowed
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Alnylam continues to extend its dominance in RNAi IP: additional Tuschl II patent granted
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Nature Biotechnology paper offers further validation for Regulus'' microRNA platform
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Alnylam continues to execute and capitalize on its partnerships; gets $20M from Takeda
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S